Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ALKS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Alkermes Plc

ALKS
Current price
30.28 USD +0.14 USD (+0.46%)
Last closed 30.46 USD
ISIN USG017671052
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 5 022 883 840 USD
Yield for 12 month +29.57 %
1Y
3Y
5Y
10Y
15Y
ALKS
21.11.2021 - 28.11.2021

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, D04 C5Y6

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

41.07 USD

P/E Ratio

14.50

Dividend Yield

Financials ALKS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 557 632 000 USD

Last Year

+1 663 405 000 USD

Current Quarter

+306 510 000 USD

Last Quarter

+429 986 000 USD

Current Year

+1 312 301 000 USD

Last Year

+1 410 368 000 USD

Current Quarter

+306 510 000 USD

Last Quarter

+367 870 000 USD
EBITDA 419 016 992 USD
Operating Margin TTM 4.50 %
Price to Earnings 14.50
Return On Assets TTM 11.62 %
PEG Ratio -1 057.29
Return On Equity TTM 25.71 %
Wall Street Target Price 41.07 USD
Revenue TTM 1 513 769 984 USD
Book Value 9.17 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -12.50 %
Dividend Yield
Gross Profit TTM 1 277 885 952 USD
Earnings per share 2.10 USD
Diluted Eps TTM 2.10 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -40.30 %
Profit Margin 23.30 %

Stock Valuation ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 14.50
Forward PE 20.79
Enterprise Value Revenue 2.73
Price Sales TTM 3.32
Enterprise Value EBITDA 8.86
Price Book MRQ 3.27

Technical Indicators ALKS

For 52 Weeks

23.12 USD 36.45 USD
50 Day MA 30.19 USD
Shares Short Prior Month 10 562 324
200 Day MA 30.20 USD
Short Ratio 7.55
Shares Short 11 863 107
Short Percent 9.29 %